Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression...
TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...
Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression...
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor...
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna...
Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class...
TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on...
MDNA209 is a first-in-class “beta-enhanced” IL-2 Super-antagonist being developed for the potential treatment of autoimmune diseases, a disorder attributed to an imbalance of the immune system and...
TORONTO and HOUSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...
TORONTO and HOUSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.12 | -7.10059171598 | 1.69 | 1.71 | 1.27 | 93505 | 1.50838984 | CS |
| 4 | -0.66 | -29.5964125561 | 2.23 | 2.62 | 1.27 | 121595 | 1.96731176 | CS |
| 12 | -0.53 | -25.2380952381 | 2.1 | 2.62 | 1.27 | 82428 | 2.0635183 | CS |
| 26 | -0.83 | -34.5833333333 | 2.4 | 2.98 | 1.27 | 88319 | 2.13727884 | CS |
| 52 | 1.12 | 248.888888889 | 0.45 | 2.98 | 0.38 | 97328 | 1.79548736 | CS |
| 156 | -1.15 | -42.2794117647 | 2.72 | 2.98 | 0.215 | 62474 | 1.43677429 | CS |
| 260 | -0.1 | -5.9880239521 | 1.67 | 7.25 | 0.215 | 75084 | 2.75499225 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
